Eribulin in Advanced Breast Cancer: Safety, Efficacy and New Perspectives
2017; Future Medicine; Volume: 13; Issue: 30 Linguagem: Inglês
10.2217/fon-2017-0283
ISSN1744-8301
AutoresOrnella Garrone, Emanuela Miraglio, Anna Maria Vandone, Paola Vanella, Daniele Lingua, Marco Merlano,
Tópico(s)Microtubule and mitosis dynamics
ResumoEribulin is a synthetic analog of halichondrin B belonging to microtubule-targeted agents with a distinct mechanism of inhibition of microtubule dynamics. This molecule has multiple nonmitotic effects on tumor biology, exhibiting effects on epithelial-mesenchimal transition and tumor vasculature. We review here preclinical and clinical studies on eribulin. The mitotic and nonmitotic effects together with its favorable safety profile make eribulin a unique drug with high potential in the treatment of metastatic breast cancer. The new emphasis of eribulin mechanism of action on vascular remodeling, microenvironment modifications and reversal of epithelial-mesenchimal transition paves the way to rethinking the use of the drug in an immunological perspective.
Referência(s)